Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Oligometastasectomia di salvataggio e radioterapia nel carcinoma prostatico ricorrente (SOAR)

10 novembre 2026 aggiornato da: University of Utah

Oligometastasectomia di salvataggio e radioterapia nel carcinoma prostatico ricorrente (SOAR)

This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as oligometastasectomy, may remove tumor cells that have spread to other parts of the body. Surgery and radiation therapy may work better in treating patients with prostate cancer that has come back or spread to other parts of the body.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To assess response to treatment of oligometastatic disease.

SECONDARY OBJECTIVES:

I. To assess additional measurements of response to treatment of oligometastatic disease.

II. To assess prostate-specific antigen (PSA) progression free-survival following treatment of oligometastatic disease.

III. To assess time to disease recurrence following treatment of oligometastatic disease.

IV. To assess time to initiation of antiandrogen therapy (ADT) for metastatic prostate cancer following treatment of oligometastatic disease.

V. To assess the rate of undetectable PSA following treatment of oligometastatic disease in subjects who have previously undergone prostatectomy.

VI. To assess safety. VII. To assess the impact of study treatment on change in quality of life over three years.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

20

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute/University of Utah

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Histologically proven adenocarcinoma of the prostate.

  • Recurrent prostate carcinoma after definitive therapy for primary disease defined as:

    • Post-prostatectomy (with/without adjuvant radiotherapy): Patients must have a detectable or rising PSA level that is > 0.05 ng/mL, with a second confirmatory level of > 0.05 ng/mL after a minimum of 1 week.
    • Post radiotherapy/ablation (without radical prostatectomy): PSA rise >= 2ng/mL over nadir.
  • Subjects treated with prior definitive radiotherapy for prostate cancer who have positive molecular imaging (e.g., fluciclovine PET/CT scan or other per PI discretion) suggesting recurrent intraprostatic disease must undergo transrectal ultrasound (TRUS) biopsy less than or equal to one year before study enrollment:

    • If the TRUS biopsy is negative, no additional treatment is required to the prostate in addition to that of scan positive sites.
    • If the TRUS biopsy is positive, subject must undergo salvage prostatectomy or salvage radiotherapy to the primary site concurrently with the study treatment per the treatment protocol algorithm.
    • NOTE: Biopsy is not required for prostate fossa recurrences after radical prostatectomy.
  • Oligometastatic disease defined as 10 or fewer metastatic lesions to lymph nodes and/or bones only.

  • For patients with oligometastatic disease involving lymph nodes, metastasis is confined to the pelvic or para-aortic (below IMA) regions on molecular imaging (e.g., fluciclovine PET/CT or PSMA PET/CT scan or other per PI discretion).

  • All subjects must be surgical candidates if surgery is indicated per the treatment algorithm.

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2.

  • Use of condoms for male subjects who have not had surgical removal of their prostate and have a partner of child bearing potential beginning at the time of informed consent form (ICF) signature and lasting until at least 6 months after the last radiation treatment. Because of the potential side effect on spermatogenesis associated with radiation, female partners of childbearing potential must agree to use a highly effective contraceptive method during and for 6 months after completing treatment.

  • Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5 from toxicities related to any prior treatments, unless adverse event (AE)(s) are clinically non-significant and/or stable on supportive therapy as determined by the treating physician.

  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

  • Known brain or visceral metastases other than lymph nodes as defined by CT, MRI, or othermolecular imaging (e.g., fluciclovine PET/CT or PSMA PET/CT scan or other per PI discretion).

  • Patients actively receiving hormone therapy for prostate cancer. Patients may have received hormone therapy perviously but must have documented non-castrate levels of testosterone (>50 ng/dL)

  • Prior or concurrent malignancy whose natural history or treatment, in the opinion of the enrolling investigator, may have the potential to interfere wih the safety or efficay assessment of the investigational treatment protocol of the study.

  • Use of finasteride within 30 days prior to initiation of therapy. Baseline PSA should not be obtained prior to 30 days after stopping finasteride.

  • Use of dutasteride within 90 days prior to initiation of therapy. Baseline PSA should not be obtained prior to 90 days after stopping dutasteride.

  • Use of any prohibited therapy.

  • Active, uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders:

      • Congestive heart failure New York Heart Association class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.
      • Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mmHg systolic or > 100 mmHg diastolic despite optimal antihypertensive treatment.
      • Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose.
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration or within 30 days of registration.

    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A (radiation therapy)

Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Ancillary studies

Undergo hypofractionated radiation therapy

Altri nomi:
  • Radioterapia ipofrazionata
  • ipofrazionamento

Undergo SBRT

Altri nomi:
  • SBR
  • SAB
  • Radioterapia corporea ablativa stereotassica
Sperimentale: Arm B (salvage oligometastasectomy)

Patients with nodal metastases undergo salvage oligometastasectomy.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Ancillary studies

Undergo salvage oligometastasectomy

Sperimentale: Arm C (salvage oligometastasectomy, radiation therapy)

Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Ancillary studies

Undergo IMRT

Altri nomi:
  • IMRT
  • Intensità modulata RT
  • Radioterapia a intensità modulata

Undergo hypofractionated radiation therapy

Altri nomi:
  • Radioterapia ipofrazionata
  • ipofrazionamento

Undergo SBRT

Altri nomi:
  • SBR
  • SAB
  • Radioterapia corporea ablativa stereotassica

Undergo salvage oligometastasectomy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Prostate-specific Antigen (PSA) ≥ 50% 6 Months After Completion of All Treatment
Lasso di tempo: 6 months after completion of 5-21 weeks of treatment

The primary outcome measure will report the count of patients achieving a PSA decline >= 50% at 6 months after completion of treatment (salvage + - adjuvant).

Prostate-Specific Antigen (PSA) is a protein produced by tissue in the prostate. An elevated PSA value can be a sign of prostate cancer.

6 months after completion of 5-21 weeks of treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Prostate-specific Antigen (PSA) ≥ 50% 12 Months After Completion of All Treatment
Lasso di tempo: 12 months after completion of 5-21 weeks of treatment

Defined according to Prostate Cancer Working Group (PCWG3) criteria as the proportion of patients achieving a PSA decline >= 50% at 12 months after completion of treatment (salvage + - adjuvant).

Prostate-Specific Antigen (PSA) is a protein produced by tissue in the prostate. An elevated PSA value can be a sign of prostate cancer.

12 months after completion of 5-21 weeks of treatment
Prostate-specific Antigen (PSA) ≥ 90%
Lasso di tempo: 6 and 12 months after completion of 5-21 weeks of treatment 6 Months After Completion of All Treatment6 Months After Completion of All Treatment

This outcome will report the count of patients achieving a PSA decline ≥ 90% 6 at 6 and12 months after completion of treatment (salvage + - adjuvant).

Prostate-Specific Antigen (PSA) is a protein produced by tissue in the prostate. An elevated PSA value can be a sign of prostate cancer.

6 and 12 months after completion of 5-21 weeks of treatment 6 Months After Completion of All Treatment6 Months After Completion of All Treatment
PSA Progression Free-survival
Lasso di tempo: Time elapsed between study enrollment and first occurrence of confirmed radiographic disease progression, assessed up to 3 years

The proportion of subjects without PSA progression (defined using Prostate Cancer Working Group 3 Criteria PCWG3), evaluated every 3 months for 3 years after completion of all treatment (salvage and adjuvant therapy).

Time elapsed between study enrollment and first occurrence of confirmed radiographic disease progression, assessed up to 3 years
To Assess Time to Disease Recurrence Following Treatment of Oligometastatic Disease.
Lasso di tempo: Time elapsed between study enrollment and confirmed radiographic disease progression, up to 3 years

The time from study enrollment until the date of confirmed radiographic disease progression as defined by RECIST 1.1 and PCWG3.

Time elapsed between study enrollment and confirmed radiographic disease progression, up to 3 years
To Assess Time to Initiation of ADT for Metastatic Prostate Cancer Following Treatment of Oligometastatic Disease.
Lasso di tempo: Up to 3 years

The time from study enrollment to the initiation of ADT

Up to 3 years
Undetectable PSA
Lasso di tempo: 6 and 12 months after completion of 5-21 weeks of treatment

This outcome measure will report the count of participants with undetectable PSA after 6 and 12 months following completion of treatment (salvage ± adjuvant). Undetectable PSA is defined as the number of patients ever treated with prostatectomy whose PSA remains ≤ 0.2 ng/mL.

6 and 12 months after completion of 5-21 weeks of treatment
Number of Participants With Adverse Events (AE) by Grade
Lasso di tempo: Up to 12 months after completion of 5-21 weeks of treatment

This outcome measure will assess the safety and tolerability of the study treatment.

The severity of AEs was assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE".

This outcome measure will report the count of participants who experienced each AE grade. Subjects were monitored for adverse events from the start of treatment until 28 days after the last dose of the study drug.

Adverse events were collected every three months for one year after treatment discontinuation.

Up to 12 months after completion of 5-21 weeks of treatment
Quality of Life (QOL) - The Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Lasso di tempo: up to 45 days after the initiation of study therapy

FACT-P is a QOL questionnaires administered at the Response Assessment Visit. FACT-P is used to assess the health-related QOL in prostate cancer. Patients indicate which symptoms/problems they've experienced during the past week, from 1 Not at All to 4 Very Much.

The assessment was scored according to the "FACT-P Scoring Guidelines (Version 4)". Individual items that were "reverse items" (high value indicates poor QOL) were subtracted from 4; reverse and normal items were added to calculate each subscale. The higher the subscale the better the QOL. The subscales and score ranges are: Physical Well-Being (0-28), Social/ Family Well Being (0-28), Emotional Well-Being (0-24), Functional Well Being (0-28), and Prostate Cancer Subscale (0-48)

This outcome will report the mean score and 95% confidence interval of each subscale.

up to 45 days after the initiation of study therapy
Quality of Life (QOL): Expanded Prostate Cancer Index Composite (EPIC-26)
Lasso di tempo: up to 45 days after initiation of study therapy

EPIC-26 is a Health Related Quality of Life (HRQOL) questionnaires assessing the disease-specific aspects of prostate cancer and its therapies. This questionnaire asks patients to rank symptoms from 1 More than once a day to 5 Rarely or never.

EPOC-26 reports 5 subscales: Urinary Incontinence Score, Urinary Obstructive/ Irritative Score, Bowel Score, Sexual Score, and Urinary Incontinence Score. Multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.

up to 45 days after initiation of study therapy

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Alejandro Sanchez, Huntsman Cancer Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 settembre 2019

Completamento primario (Effettivo)

13 febbraio 2024

Completamento dello studio (Effettivo)

11 marzo 2026

Date di iscrizione allo studio

Primo inviato

4 gennaio 2019

Primo inviato che soddisfa i criteri di controllo qualità

4 gennaio 2019

Primo Inserito (Effettivo)

8 gennaio 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 115811
  • NCI-2018-03418 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .